全文获取类型
收费全文 | 26748篇 |
免费 | 4294篇 |
国内免费 | 1168篇 |
专业分类
耳鼻咽喉 | 217篇 |
儿科学 | 598篇 |
妇产科学 | 326篇 |
基础医学 | 4801篇 |
口腔科学 | 712篇 |
临床医学 | 2602篇 |
内科学 | 6149篇 |
皮肤病学 | 675篇 |
神经病学 | 2049篇 |
特种医学 | 612篇 |
外国民族医学 | 13篇 |
外科学 | 2402篇 |
综合类 | 3324篇 |
一般理论 | 1篇 |
预防医学 | 1473篇 |
眼科学 | 409篇 |
药学 | 2071篇 |
8篇 | |
中国医学 | 392篇 |
肿瘤学 | 3376篇 |
出版年
2024年 | 20篇 |
2023年 | 508篇 |
2022年 | 595篇 |
2021年 | 1270篇 |
2020年 | 1357篇 |
2019年 | 1482篇 |
2018年 | 1352篇 |
2017年 | 1353篇 |
2016年 | 1407篇 |
2015年 | 1469篇 |
2014年 | 1846篇 |
2013年 | 1892篇 |
2012年 | 1805篇 |
2011年 | 1927篇 |
2010年 | 1663篇 |
2009年 | 1524篇 |
2008年 | 1477篇 |
2007年 | 1301篇 |
2006年 | 1182篇 |
2005年 | 960篇 |
2004年 | 767篇 |
2003年 | 770篇 |
2002年 | 626篇 |
2001年 | 582篇 |
2000年 | 475篇 |
1999年 | 337篇 |
1998年 | 271篇 |
1997年 | 247篇 |
1996年 | 152篇 |
1995年 | 165篇 |
1994年 | 159篇 |
1993年 | 130篇 |
1992年 | 126篇 |
1991年 | 84篇 |
1990年 | 81篇 |
1989年 | 70篇 |
1988年 | 70篇 |
1987年 | 52篇 |
1986年 | 61篇 |
1985年 | 100篇 |
1984年 | 74篇 |
1983年 | 65篇 |
1982年 | 44篇 |
1981年 | 56篇 |
1980年 | 59篇 |
1979年 | 33篇 |
1978年 | 40篇 |
1977年 | 21篇 |
1976年 | 34篇 |
1975年 | 17篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
《The Journal of thoracic and cardiovascular surgery》2023,165(1):327-334.e2
ObjectiveSeveral trials have recently reported the safety of pulmonary resection after neoadjuvant immunotherapy with encouraging major pathological response rates. We report the detailed adverse events profile from a recently conducted randomized phase II trial in patients with resectable non–small cell lung cancer treated with neoadjuvant durvalumab alone or with sub-ablative radiation.MethodsWe conducted a randomized phase II trial in patients with non–small cell lung cancer clinical stages I to IIIA who were randomly assigned to receive neoadjuvant durvalumab alone or with sub-ablative radiation (8Gyx3). Secondary end points included the safety of 2 cycles of preoperative durvalumab with and without radiation followed by pulmonary resection. Postoperative adverse events within 30 days were recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).ResultsSixty patients were enrolled and randomly assigned, with planned resection performed in 26 patients in each arm. Baseline demographics and clinical variables were balanced between groups. The median operative time was similar between arms: 128 minutes (97-201) versus 146 minutes (109-214) (P = .314). There was no 30- or 90-day mortality. Grade 3/4 adverse events occurred in 10 of 26 patients (38%) after monotherapy and in 10 of 26 patients (38%) after dual therapy. Anemia requiring transfusion and hypotension were the 2 most common adverse events. The median length of stay was similar between arms (5 days vs 4 days, P = .172).ConclusionsIn this randomized trial, the addition of sub-ablative focal radiation to durvalumab in the neoadjuvant setting was not associated with increased mortality or morbidity compared with neoadjuvant durvalumab alone. 相似文献
3.
4.
5.
- DNA is the sequence that codes for proteins.
- Messenger RNA is transcribed from the DNA sequence of genes and translated into protein.
- It can be difficult to predict how a change in the DNA sequence will affect messenger RNA and protein quantity and quality.
- DNA translocation changes can cause the joining of sequences from two different genes or different parts of the same gene.
- DNA sequencing is often used clinically to predict how DNA changes might affect proteins.
- Alternatively, RNA sequencing can be used as a more direct measure of the effect of DNA changes on the protein products.
- This sequencing is important for identifying changes in cancer that may indicate response to targeted therapy, prognosis, or diagnosis.
6.
7.
《Journal of vascular and interventional radiology : JVIR》2022,33(8):964-971.e2
PurposeTo assess the cost effectiveness of microwave ablation (MWA) and stereotactic body radiotherapy (SBRT) for patients with inoperable stage I non–small cell lung cancer (NSCLC).Materials and MethodsA literature search was performed in MEDLINE with broad search clusters. A decision-analytic model was constructed over a 5-year period. The model incorporated treatment-related complications and long-term recurrence. All clinical parameters were derived from the literature with preference to long-term prospective trials. A healthcare payers’ perspective was adopted. Outcomes were measured in quality-adjusted life years (QALYs) extracted from prior studies and U.S. dollars from Medicare reimbursements and prior studies. Base case calculations, probabilistic sensitivity analysis with 10,000 Monte Carlo simulations, and multiple 1- and 2-way sensitivity analyses were performed.ResultsMWA yielded a health benefit of 2.31 QALYs at a cost of $195,331, whereas SBRT yielded a health benefit of 2.33 QALYs at a cost of $225,271. The incremental cost-effectiveness ratio was $1,480,597/QALY, indicating that MWA is the more cost-effective strategy. The conclusion remains unchanged in probabilistic sensitivity analysis with MWA being the optimal cost strategy in 99.84% simulations. One-way sensitivity analyses revealed that MWA remains cost effective when its annual recurrence risk is <18.4% averaged over 5 years, when the SBRT annual recurrence risk is >1.44% averaged over 5 years, or when MWA is at least $7,500 cheaper than SBRT.ConclusionsMWA appears to be more cost effective than SBRT for patients with inoperable stage I NSCLC. 相似文献
8.
9.
手术治疗特别是中耳病变切除联合鼓室成形术是目前根治中耳胆脂瘤最主要的方法,依据2012年版的中耳炎手术分型指南内容,按照手术对外耳道后壁和鼓窦上鼓室侧壁处理方式不同,中耳病变切除具体类型和对应ICD-9-CM-3编码为:完壁式乳突根治术20.4900x009、开放式乳突根治术20.4900x008、完桥式乳突根治术20.49和上鼓室鼓窦切开术20.4900x007等,为避免上述手术编码的混淆,编码员应掌握每种术式的具体内涵。同时对于重要的其它手术操作如鼓室成形术19.4~19.5、耳甲腔成形术18.79、外耳道后壁重建术18.6和乳突缩窄术20.92等也不能漏编和多编。编码员应加强中耳结构和手术知识的学习,当不能确定手术具体类型时,应与耳鼻喉医师沟通,确定正确手术类型和内容时方可编码。 相似文献
10.
Dan-Dan Shan Qiu-Xian Zheng Jing Wang Zhi Chen 《World journal of gastroenterology : WJG》2022,28(16):1641-1655
Cancer has become the most life-threatening disease in the world. Mutations in and aberrant expression of genes encoding proteins and mutations in noncoding RNAs, especially long noncoding RNAs (lncRNAs), have significant effects in human cancers. LncRNAs have no protein-coding ability but function extensively in numerous physiological and pathological processes. Small nucleolar RNA host gene 3 (SNHG3) is a novel lncRNA and has been reported to be differentially expressed in various tumors, such as liver cancer, gastric cancer, and glioma. However, the interaction mechanisms for the regulation between SNHG3 and tumor progression are poorly understood. In this review, we summarize the results of SNHG3 studies in humans, animal models, and cells to underline the expression and role of SNHG3 in cancer. SNHG3 expression is upregulated in most tumors and is detrimental to patient prognosis. SNHG3 expression in lung adenocarcinoma remains controversial. Concurrently, SNHG3 affects oncogenes and tumor suppressor genes through various mechanisms, including competing endogenous RNA effects. A deeper understanding of the contribution of SNHG3 in clinical applications and tumor development may provide a new target for cancer diagnosis and treatment. 相似文献